InnoCan Pharma Corporation (CSE:INNO)

Market Cap	22.49M -64.8%
Revenue (ttm)	36.49M -9.6%
Net Income	-1.54M
EPS	-0.34
Shares Out	4.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002
Average Volume	889
Open	4.750
Previous Close	5.000
Day's Range	4.000 - 4.750
52-Week Range	4.000 - 21.000
Beta	-0.25
RSI	24.54
Earnings Date	Apr 14, 2026

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The comp...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2017
• Employees: 5
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2025, InnoCan Pharma's revenue was $26.61 million, a decrease of -9.60% compared to the previous year's $29.44 million. Losses were -$1.12 million, -38.71% less than in 2024.

Financial numbers in USD